dc.contributorDurrer Parolina de Carvalho, Rafaela
dc.creatorCarvalho, Rafaela Durrer Parolina de
dc.creatorMoreno, Jéssica de Andrade
dc.creatorRoque, Sindy Magri
dc.creatorChan, Daniel Cheuk Hong
dc.creatorTorrez, Willy Bustillos
dc.creatorStipp, Rafael Nobrega
dc.creatorBueno-Silva, Bruno
dc.creatorLima, Patrícia Oliveira de
dc.creatorMüller, Karina Cogo
dc.date.accessioned2022-12-16T13:23:04Z
dc.date.available2022-12-16T13:23:04Z
dc.identifierhttps://doi.org/10.25824/redu/ZHOMPF
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5363175
dc.descriptionObjectives: to investigate the antimicrobial activity of atorvastatin, pravastatin, rosuvastatin, and simvastatin against oral bacteria, and the interaction of SMV with standard antimicrobials (amoxicillin and metronidazole). Methods: Minimal inhibitory concentration assays were performed with Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, Actinomyces odontolyticus, Streptococcus oralis, Streptococcus mitis, Streptococcus salivarius, Streptococcus sanguinis, and Streptococcus gordonii; checkerboard microdilution assays between simvastatin and standard antimicrobials; monospecies and multispecies biofilms. Results: simvastatin showed the best antimicrobial activity against most species (MIC range from 3.12 to 25 µg/mL), highlighting the sensitivity of P. gingivalis. In the checkerboard assay, synergistic interaction was found between simvastatin and amoxicillin against S. oralis and S. sanguinis. P. gingivalis biofilm was inhibited by simvastatin at 10 and 50x Minimal inhibitory concentration, with similar effects to metronidazole. For multispecies biofilm, SMV reduced the biofilm metabolic activity (79%) and total counts (87%), comparable to amoxicillin. simvastatin also reduced bacterial counts of Veilonnella parvula, P. gingivalis, Streptococcus mutans, Actinomyces naeslundii, P. intermedia, and Capnocytophaga ochracea in the multispecies biofilm. Conclusions: Simvastatin showed antimicrobial and antibiofilm activity against oral bacteria and may contribute to the control of dysbiosis, and may be considered in clinical studies as an adjuvant in the treatment of periodontitis.
dc.publisherRepositório de Dados de Pesquisa da Unicamp
dc.subjectChemistry
dc.subjectMedicine, Health and Life Sciences
dc.subjectStatins
dc.subjectSimvastatin
dc.subjectDrug repositioning
dc.subjectPeriodontal diseases
dc.subjectAntimicrobial agents
dc.titleAntimicrobial activity of statins against bacteria of the oral microbiota


Este ítem pertenece a la siguiente institución